Video

Colorectal Cancer Makeup May Differ by Age Group

Recent research found that patients under 50 were less likely to have a treatment-determining biomarker than their older counterparts.

Molecular makeup may differ between age groups of patients with colorectal cancer, according to research conducted by Aaron Franke, M.D., incoming hematology/oncology fellow at the University of Southern Florida/H. Lee Moffitt Cancer Center.

There has been an increase in colorectal cancer in younger populations in recent years. However, in research Franke conducted through the GI Oncology Department at the University of Florida, it was found that biomarkers, such as microsatellite instability-high (MSI-H) status, are seen less frequently in patients under 50 years of age. When it comes to the over-50 population, previous research found that less than one-third of these patients are undergoing genetic testing, although they may be more likely than their younger counterparts to test positive for MSI-H, which can have important treatment and prognostic implications.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content